| abstract |
The present invention relates to the treatment of, for example, heart failure (particularly congestive heart failure), chronic kidney disease, end-stage renal disease, liver disease and peroxisome proliferator-activated receptor (PPAR) gamma agonist-induced fluid retention etc. Compounds and methods for conditions related to retention or salt overload. The invention also relates to compounds and methods useful in the treatment of hypertension. The invention also relates to compounds and methods for treating gastrointestinal disorders, including treating or alleviating pain associated with gastrointestinal disorders. The methods generally comprise administering to a mammal in need thereof a pharmaceutically effective amount of a compound, or a pharmaceutical composition comprising the compound, designed to act substantially in the gastrointestinal (GI) tract. The effect is to inhibit the reverse transport of sodium ions and hydrogen ions mediated by NHE. |